Eam Investors, LLC Immunovant, Inc. Transaction History

Eam Investors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$30.27 - $43.79 $1.26 Million - $1.83 Million	-41,688 Reduced 37.58%	69,241 $2.24 Million
Q4 2023 Feb 13, 2024	BUY	$31.31 - $44.19 $263,285 - $371,593	8,409 Added 8.2%	110,929 $4.67 Million
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $1.16 Million - $2.51 Million	62,724 Added 157.61%	102,520 $3.94 Million
Q2 2023 Aug 11, 2023	BUY	$14.2 - $23.75 $565,103 - $945,155	39,796 New	39,796 $754,000
Q1 2021 May 11, 2021	SELL	$13.08 - $49.6 $425,073 - $1.61 Million	-32,498 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$36.36 - $52.71 $105,262 - $152,595	-2,895 Reduced 8.18%	32,498 $1.5 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $800,235 - $1.38 Million	35,393 New	35,393 $1.25 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.